|
|
||||||||||
|
J Am Coll Cardiol, 2001; 37:719-725 © 2001 by the American College of Cardiology Foundation |



* Department of Geriatric Medicine, Osaka University Medical School, Suita, Osaka, Japan
Division of Cardiology, Ibaraki Iseikai Hospital, Ibaraki, Osaka, Japan
Manuscript received April 27, 2000; revised manuscript received September 28, 2000, accepted November 3, 2000.
Reprint requests and correspondence: Dr. Jitsuo Higaki, Department of Geriatric Medicine, Osaka University Medical School, Yamadaoka 2-2 B6, Suita 565-0871, Japan
higaki{at}geriat.med.osaka-u.ac.jp
OBJECTIVES
We examined whether patients with ischemic heart disease (IHD) should be treated with nicorandil, an adenosine triphosphate-sensitive potassium channel opener, in addition to the regular use of nitrates.
BACKGROUND
It has been reported that nicorandil possibly has additive effects on nitroglycerin (NTG) treatment for angina, but the mechanism is not clear.
METHODS
We directly measured anterograde coronary blood flow (CBF) with a Doppler guide wire to examine the effects of intravenous administration of NTG (0.3 mg) and nicorandil (6 mg) during continuous administration of NTG at a sufficient dose (25 µg/min) in subjects with normal and stenotic coronary arteries.
RESULTS
Additional systemic administration of NTG decreased anterograde CBF (normal 19.7%; stenotic 21.2%). In contrast, nicorandil increased anterograde CBF in both normal (54.6%) and stenotic (89.6%) coronary arteries, without the coronary steal phenomenon. There was a tendency toward nicorandil-dilated diameters in the patients with stenotic arteries (p = 0.06). There were no effects of additional administration on pulmonary artery wedge pressure. There was no difference in changes in heart rate and mean aortic blood pressure between NTG and nicorandil therapy.
CONCLUSIONS
These results suggest that in patients treated with nitrates, additional administration of nicorandil is more useful, in terms of increasing CBF, than additional administration of nitrates. Adjunctive use of nicorandil with nitrates may provide the further benefit of myocardial protection and may improve the prognosis of patients with IHD.
| ||||||||||||||||||||||
This article has been cited by other articles:
![]() |
H. Ishii, S. Ichimiya, M. Kanashiro, T. Amano, T. Matsubara, and T. Murohara Effects of Intravenous Nicorandil Before Reperfusion for Acute Myocardial Infarction in Patients With Stress Hyperglycemia Diabetes Care, February 1, 2006; 29(2): 202 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ishii, S. Ichimiya, M. Kanashiro, T. Amano, K. Imai, T. Murohara, and T. Matsubara Impact of a Single Intravenous Administration of Nicorandil Before Reperfusion in Patients With ST-Segment-Elevation Myocardial Infarction Circulation, August 30, 2005; 112(9): 1284 - 1288. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Okamura, H. Ito, K. Iwakura, S. Kawano, K. Inoue, Y. Maekawa, T. Ogihara, and K. Fujii Detection of embolic particles with the Doppler guide wire during coronary intervention in patients with acute myocardial infarction: Efficacy of distal protection device J. Am. Coll. Cardiol., January 18, 2005; 45(2): 212 - 215. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Inokuchi, Y. Hirooka, H. Shimokawa, K. Sakai, T. Kishi, K. Ito, Y. Kimura, and A. Takeshita Role of Endothelium-Derived Hyperpolarizing Factor in Human Forearm Circulation Hypertension, November 1, 2003; 42(5): 919 - 924. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |